glp-1 obesity drug news today oct 2025 Genetics: How Genes Affect Appetite, Semaglutide, and Tirzepatide Response McKee's proposed FY2027 budget drops

Weight loss was consistent and progressive, starting at 3.93% at three months and reaching 7.87% at twelve months. In addition, several case series studies have demonstrated benefits of GLP-1s in kidney and pancreas transplant recipients, including lowering blood glucose levels and providing renal protective effects. GLP-1 RAs would be advantageous in liver transplant recipients due to their renal clearance, avoiding interference with immunosuppressant drug metabolism

A recent meta-analysis involving 32,884 patients from 19 randomized controlled trials further confirmed a 23% reduction in all-cause mortality associated with GLP-1RAs use (OR = 0.77) (Rivera et al., 2024)

The relative risks of complications, including progression of CKD to end-stage kidney disease (ESKD), CVD and mortality, are increased with both reduced eGFR and elevated UACR levels [1]

How Levels offers a new approach to weight management Learn more about Levels' approach to sustainable weight management Finally, GLP-1 acts directly on your nervous system

Outside of those major clinical trials, a nationwide retrospective study in Taiwan, China, evaluated the effects of DPP-4i in elderly patients with T2DM relative to cardiovascular outcomes